Boston Scientific (BSX) vs. Agilent Technologies (A) Head to Head Analysis

Boston Scientific (NYSE: BSX) and Agilent Technologies (NYSE:A) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Volatility & Risk

Boston Scientific has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.


This table compares Boston Scientific and Agilent Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Boston Scientific 9.55% 23.60% 9.24%
Agilent Technologies 15.30% 16.96% 9.43%

Valuation & Earnings

This table compares Boston Scientific and Agilent Technologies’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Boston Scientific $8.39 billion 4.18 $347.00 million $0.61 41.80
Agilent Technologies $4.47 billion 4.82 $684.00 million $2.10 31.90

Agilent Technologies has lower revenue, but higher earnings than Boston Scientific. Agilent Technologies is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

90.6% of Boston Scientific shares are held by institutional investors. 0.7% of Boston Scientific shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


Agilent Technologies pays an annual dividend of $0.53 per share and has a dividend yield of 0.8%. Boston Scientific does not pay a dividend. Agilent Technologies pays out 25.2% of its earnings in the form of a dividend.

Analyst Recommendations

This is a summary of recent recommendations for Boston Scientific and Agilent Technologies, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Boston Scientific 0 3 13 1 2.88
Agilent Technologies 0 3 9 0 2.75

Boston Scientific currently has a consensus price target of $30.83, indicating a potential upside of 20.92%. Agilent Technologies has a consensus price target of $69.23, indicating a potential upside of 3.32%. Given Boston Scientific’s stronger consensus rating and higher possible upside, research analysts plainly believe Boston Scientific is more favorable than Agilent Technologies.


Boston Scientific beats Agilent Technologies on 9 of the 17 factors compared between the two stocks.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Agilent Technologies Company Profile

Agilent Technologies, Inc. provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business. Its life sciences and applied markets business segment offers instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Its diagnostics and genomics business segment includes the reagent partnership, pathology, companion diagnostics, genomics and the nucleic acid solutions businesses. Its Agilent CrossLab business segment spans the entire lab with its consumables and services portfolio.

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with's FREE daily email newsletter.

Leave a Reply